MANAGED ACCESS PROGRAM (MAP) TO PROVIDE ACCESS TO CTL019, FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LARGE B-CELL LYMPHOMA PATIENTS WITH OUT OF SPECIFICATION LEUKAPHERESIS PRODUCT AND/OR MANUFACTURED TISAGENLECLEUCEL OUT OF SPECIFICATION FOR COMMERCIAL RELEASE
- Registry ID
- CCTL019B2003I
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Last update
- 2022-03-25
Conditions
- RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Related clinical trials
- PHASE I MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF BMS-986497 (ORM-6151) IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME
- AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
- A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
- PHASE III RANDOMIZED, DOUBLE-LIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY OF THE ADDITION OF CRENOLANIB TO SALVAGE CHEMOTHERAPY VERSUS SALVAGE CHEMOTHERAPY ALONE IN SUBJECT<75 YEARS OF AGE WITH RELAPSED/REFRACTORY FLT3 MUTATED ACUTE
- A PHASE 1 FIRST-IN-HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF AMG 427 IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
- A PHASE 1/2, MULTICENTER, DOSE-ESCALATION AND EXPANSION STUDY OF COMBINATION THERAPY WITH VENETOCLAX, DARATUMUMAB AND DEXAMETHASONE (WITH AND WITHOUT BORTEZOMIB) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
View on source registry